Gene Methylation Profile in Hematologic Malignancies

Mariia Andreevna Mikhaleva, A.A. Zherniakova, O.B. Krysiuk, S.V. Sidorkevich,

DOI:

https://doi.org/10.21320/2500-2139-2026-19-1-27-38

Hematologic malignancies are characterized by a pronounced heterogeneity of tumor clone accounted for by both gene abnormalities and epigenetic changes including abnormal DNA methylation as well as impaired regulation of histone modifications and non-coding RNAs. Recent developments in high-throughput sequencing technology confirmed the key role of epigenetic modifications in the regulation of dynamic biological processes. Over the past years, a considerable body of knowledge has been generated to document the effect of changing epigenetic mechanisms on the development and further progression of hematologic tumors. The analysis of methylation profile leads to detecting the unique epigenetic signatures correlating with clinical outcomes and refractoriness to chemotherapy. This review systematizes current views on the role of DNA methylation in oncohematology and various methods of its analysis as well as the outlook for the therapy targeting the epigenetic abnormalities.

  1. Guillamot M, Cimmino L, Aifantis I. The impact of DNA methylation in hematopoietic malignancies. Trends Cancer. 2016;2(2):70–83. doi: 10.1016/j.trecan.2015.12.006. DOI: https://doi.org/10.1016/j.trecan.2015.12.006
  2. Blecua P, Martinez-Verbo L, Esteller M. The DNA methylation landscape of hematological malignancies: an update. Mol Oncol. 2020;14(8):1616–39. doi: 10.1002/1878-0261.12744. DOI: https://doi.org/10.1002/1878-0261.12744
  3. Pechalrieu D, Etievant C, Arimondo PB. DNA methyltransferase inhibitors in cancer: from pharmacology to translational studies. Biochem Pharmacol. 2017;129:1–13. doi: 10.1016/j.bcp.2016.12.004. DOI: https://doi.org/10.1016/j.bcp.2016.12.004
  4. Shanmugam G, Rakshit S, Sarkar K. HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases. Transl Oncol. 2022;16:101312. doi: 10.1016/j.tranon.2021.101312. DOI: https://doi.org/10.1016/j.tranon.2021.101312
  5. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148–59. doi: 10.1056/NEJMra072067. DOI: https://doi.org/10.1056/NEJMra072067
  6. Лавров С.А., Кибанов М.В. Некодирующие РНК и структура хроматина. Успехи биологической химии. 2007;47:53–88. [Lavrov S.A., Kibanov M.V. Non-coding RNAs and chromatin structure. Uspekhi biologicheskoi khimii. 2007;47:53–88. (In Russ)]
  7. Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene. 2007;26(47):6697–714. doi: 10.1038/sj.onc.1210755. DOI: https://doi.org/10.1038/sj.onc.1210755
  8. Zhao A, Wang B, Chen C, et al. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Sig Transduct Target Ther. 2023;8(1):71. doi: 10.1038/s41392-023-01342-6. DOI: https://doi.org/10.1038/s41392-023-01342-6
  9. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447(7143):407–12. doi: 10.1038/nature05915. DOI: https://doi.org/10.1038/nature05915
  10. Heintzman ND, Stuart RK, Hon G, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007;39(3):311–8. doi: 10.1038/ng1966. DOI: https://doi.org/10.1038/ng1966
  11. Spektor R, Tippens ND, Mimoso CA, et al. methyl-ATAC-seq measures DNA methylation at accessible chromatin. Genome Res. 2019;29(6):969–77. doi: 10.1101/gr.245399.118. DOI: https://doi.org/10.1101/gr.245399.118
  12. Al Ojaimi M, Banimortada BJ, Othman A, et al. Disorders of histone methylation: molecular basis and clinical syndromes. Clin Genet. 2022;102(3):169–81. doi: 10.1111/cge.14181. DOI: https://doi.org/10.1111/cge.14181
  13. Liu M-K, Sun X-J, Gao X-D, et al. Methylation alterations and advance of treatment in lymphoma. Front Biosci. 2021;26(9):602–13. doi: 10.52586/4970. DOI: https://doi.org/10.52586/4970
  14. Ward M, McEwan C, Mills JD, Janitz M. Conservation and tissue-specific transcription patterns of long noncoding RNAs. J Hum Transcr. 2015;1(1):2–9. doi: 10.3109/23324015.2015.1077591. DOI: https://doi.org/10.3109/23324015.2015.1077591
  15. Liu Y, Cheng Z, Pang Y, et al. Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol. 2019;12(1):51. doi: 10.1186/s13045-019-0734-5. DOI: https://doi.org/10.1186/s13045-019-0734-5
  16. Bartel DP. Metazoan MicroRNAs. Cell. 2018;173(1):20–51. doi: 10.1016/j.cell.2018.03.006. DOI: https://doi.org/10.1016/j.cell.2018.03.006
  17. Chaidos A, Caputo V, Karadimitris A. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol. 2015;6(3):128–41. doi: 10.1177/2040620715576662. DOI: https://doi.org/10.1177/2040620715576662
  18. Yan J, Diaz J, Jiao J, et al. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma. J Biol Chem. 2011;286(31):27663–75. doi: 10.1074/jbc.M111.246975. DOI: https://doi.org/10.1074/jbc.M111.246975
  19. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 1996;384(6610):641–3. doi: 10.1038/384641a0. DOI: https://doi.org/10.1038/384641a0
  20. Brown JA. Patent spotlight: small-molecule lysine acetyltransferase inhibitors (KATi). Pharm Pat Anal. 2020;9(1):17–28. doi: 10.4155/ppa-2019-0025. DOI: https://doi.org/10.4155/ppa-2019-0025
  21. Yang Y, Kueh AJ, Grant ZL, et al. The histone lysine acetyltransferase HBO1 (KAT7) regulates hematopoietic stem cell quiescence and self-renewal. Blood. 2022;139(6):845–58. doi: 10.1182/blood.2021013954. DOI: https://doi.org/10.1182/blood.2021013954
  22. Lemercier C, Brocard MP, Puvion-Dutilleul F, et al. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem. 2002;277(24):22045–52. doi: 10.1074/jbc.M201736200. DOI: https://doi.org/10.1074/jbc.M201736200
  23. Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009;54(6):688–98. doi: 10.1111/j.1365-2559.2009.03290.x. DOI: https://doi.org/10.1111/j.1365-2559.2009.03290.x
  24. Barneda-Zahonero B, Collazo O, Azagra A, et al. The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma. Cell Death Dis. 2015;6(2):e1635. doi: 10.1038/cddis.2014.594. DOI: https://doi.org/10.1038/cddis.2014.594
  25. Bae J, Hideshima T, Tai YT, et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018;32(9):1932–47. doi: 10.1038/s41375-018-0062-8. DOI: https://doi.org/10.1038/s41375-018-0062-8
  26. Ruzic D, Djoković N, Srdić-Rajić T, et al. Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics. 2022;14(1):209. doi: 10.3390/pharmaceutics14010209. DOI: https://doi.org/10.3390/pharmaceutics14010209
  27. Coles AH, Jones SN. The ING gene family in the regulation of cell growth and tumorigenesis. J Cell Physiol. 2009;218(1):45–57. doi: 10.1002/jcp.21583. DOI: https://doi.org/10.1002/jcp.21583
  28. Dialynas GK, Vitalini MW, Wallrath LL. Linking Heterochromatin Protein 1 (HP1) to cancer progression. Mutat Res. 2008;647(1–2):13–20. doi: 10.1016/j.mrfmmm.2008.09.007. DOI: https://doi.org/10.1016/j.mrfmmm.2008.09.007
  29. Wang GG, Song J, Wang Z, et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature. 2009;459(7248):847–51. doi: 10.1038/nature08036. DOI: https://doi.org/10.1038/nature08036
  30. Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci USA. 2003;100(14):8342–7. doi: 10.1073/pnas.1436338100. DOI: https://doi.org/10.1073/pnas.1436338100
  31. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303. doi: 10.1038/nature10351. DOI: https://doi.org/10.1038/nature10351
  32. Castiglioni S, Di Fede E, Bernardelli C, et al. KMT2A: Umbrella Gene for Multiple Diseases. Genes (Basel). 2022;13(3):514. doi: 10.3390/genes13030514. DOI: https://doi.org/10.3390/genes13030514
  33. Leeman-Neill RJ, Soderquist CR, Montanari F, et al. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica. 2022;107(1):201–10. doi: 10.3324/haematol.2020.267294. DOI: https://doi.org/10.3324/haematol.2020.267294
  34. Zhang J, Dominguez-Sola D, Hussein S, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21(10):1190–8. doi: 10.1038/nm.3940. DOI: https://doi.org/10.1038/nm.3940
  35. Papakonstantinou N, Ntoufa S, Chartomatsidou E, et al. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. Oncotarget. 2016;7(24):35946–59. doi: 10.18632/oncotarget.9371. DOI: https://doi.org/10.18632/oncotarget.9371
  36. Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011;117(8):2451–9. doi: 10.1182/blood-2010-11-321208. DOI: https://doi.org/10.1182/blood-2010-11-321208
  37. Yan J, Ng SB, Tay JL, et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood. 2013;121(22):4512–20. doi: 10.1182/blood-2012-08-450494. DOI: https://doi.org/10.1182/blood-2012-08-450494
  38. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118(13):3645–56. doi: 10.1182/blood-2011-04-346643. DOI: https://doi.org/10.1182/blood-2011-04-346643
  39. Greenblatt SM, Man N, Hamard PJ, et al. CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell. 2018;33(6):1111–27.e5. doi: 10.1016/j.ccell.2018.05.007. DOI: https://doi.org/10.1016/j.ccell.2018.05.007
  40. Shokri G, Doudi S, Fathi-Roudsari M, et al. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view. Leuk Res. 2018;68:105–11. doi: 10.1016/j.leukres.2018.02.003. DOI: https://doi.org/10.1016/j.leukres.2018.02.003
  41. Zhang S, Liu M, Yao Y, et al. Targeting LSD1 for acute myeloid leukemia (AML) treatment. Pharmacol Res. 2021;164:105335. doi: 10.1016/j.phrs.2020.105335. DOI: https://doi.org/10.1016/j.phrs.2020.105335
  42. Xu S, Wang S, Xing S, et al. KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2. Blood Adv. 2021;5(17):3241–53. doi: 10.1182/bloodadvances.2020002819. DOI: https://doi.org/10.1182/bloodadvances.2020002819
  43. Tatsumi G, Kawahara M, Yamamoto R, et al. LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia. Leukemia. 2020;34(3):746–58. doi: 10.1038/s41375-019-0614-6. DOI: https://doi.org/10.1038/s41375-019-0614-6
  44. Hu X, Li X, Valverde K, et al. LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis. Proc Natl Acad Sci USA. 2009;106(25):10141–6. doi: 10.1073/pnas.0900437106. DOI: https://doi.org/10.1073/pnas.0900437106
  45. Kohrogi K, Hino S, Sakamoto A, et al. LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα. Blood Adv. 2021;5(9):2305–18. doi: 10.1182/bloodadvances.2020003521. DOI: https://doi.org/10.1182/bloodadvances.2020003521
  46. Xue S, Lam YM, He Z, et al. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions. Exp Hematol. 2020;82:53–65. doi: 10.1016/j.exphem.2020.01.006. DOI: https://doi.org/10.1016/j.exphem.2020.01.006
  47. Nan X, Meehan RR, Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res. 1993;21(21):4886–92. doi: 10.1093/nar/21.21.4886. DOI: https://doi.org/10.1093/nar/21.21.4886
  48. Meehan RR, Lewis JD, McKay S, et al. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell. 1989;58(3):499–507. doi: 10.1016/0092-8674(89)90430-3. DOI: https://doi.org/10.1016/0092-8674(89)90430-3
  49. Sharma ND, Nickl CK, Kang H, et al. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia. Cancer Sci. 2019;110(6):1931–46. doi: 10.1111/cas.14021. DOI: https://doi.org/10.1111/cas.14021
  50. Li Q, Lan Q, Zhang Y, et al. Role of one-carbon metabolizing pathway genes and gene-nutrient interaction in the risk of non-Hodgkin lymphoma. Cancer Causes Control. 2013;24(10):1875–84. doi: 10.1007/s10552-013-0264-3. DOI: https://doi.org/10.1007/s10552-013-0264-3
  51. Li ZY, Yang L, Liu XJ, et al. The Long Noncoding RNA MEG3 and its Target miR-147 Regulate JAK/STAT Pathway in Advanced Chronic Myeloid Leukemia. EBioMedicine. 2018;34:61–75. doi: 10.1016/j.ebiom.2018.07.013. DOI: https://doi.org/10.1016/j.ebiom.2018.07.013
  52. Harikrishnan KN, Bassal S, Tikellis C, El-Osta A. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL). Cancer Biol Ther. 2004;3(10):989–94. doi: 10.4161/cbt.3.10.1137. DOI: https://doi.org/10.4161/cbt.3.10.1137
  53. Каплун Д.С., Калюжный Д.Н., Прохорчук Е.Б., Женило С.В. Метилирование ДНК: распределение в геноме, механизм регуляции и мишень для терапии. Acta Naturae. 2022;14(4):4–19. doi: 10.32607/actanaturae.11822. [Kaplun D.S., Kaluzhny D.N., Prokhortchouk E.B., Zhenilo S.V. DNA Methylation: Genomewide Distribution, Regulatory Mechanism and Therapy Target. Acta Naturae. 2022;14(4):4–19. doi: 10.32607/actanaturae.11822. (In Russ)] DOI: https://doi.org/10.32607/actanaturae.11822
  54. Hudson NO, Buck-Koehntop BA. Zinc Finger Readers of Methylated DNA. Molecules. 2018;23(10):2555. doi: 10.3390/molecules23102555. DOI: https://doi.org/10.3390/molecules23102555
  55. Cofre J, Menezes JR, Pizzatti L, Abdelhay E. Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemia. Cancer Cell Int. 2012;12(1):28. doi: 10.1186/1475-2867-12-28. DOI: https://doi.org/10.1186/1475-2867-12-28
  56. Filion GJ, Zhenilo S, Salozhin S, et al. A family of human zinc finger proteins that bind methylated DNA and repress transcription. Mol Cell Biol. 2006;26(1):169–81. doi: 10.1128/MCB.26.1.169-181.2006. DOI: https://doi.org/10.1128/MCB.26.1.169-181.2006
  57. Prokhortchouk A, Hendrich B, Jørgensen H, et al. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev. 2001;15(13):1613–8. doi: 10.1101/gad.198501. DOI: https://doi.org/10.1101/gad.198501
  58. Gu C, Yin Z, Nie H, et al. Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1. BMC Biol. 2020;18(1):33. doi: 10.1186/s12915-020-00766-8. DOI: https://doi.org/10.1186/s12915-020-00766-8
  59. Arita K, Ariyoshi M, Tochio H, et al. Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature. 2008;455(7214):818–21. doi: 10.1038/nature07249. DOI: https://doi.org/10.1038/nature07249
  60. Avvakumov GV, Walker JR, Xue S, et al. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature. 2008;455(7214):822–5. doi: 10.1038/nature07273. DOI: https://doi.org/10.1038/nature07273
  61. Bostick M, Kim JK, Estève PO, et al. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science. 2007;317(5845):1760–4. doi: 10.1126/science.1147939. DOI: https://doi.org/10.1126/science.1147939
  62. Simonetti G, Padella A, do Valle IF, et al. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. Cancer. 2019;125(5):712–25. doi: 10.1002/cncr.31837. DOI: https://doi.org/10.1002/cncr.31837
  63. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 1998;19(3):219–20. doi: 10.1038/890. DOI: https://doi.org/10.1038/890
  64. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247–57. doi: 10.1016/s0092-8674(00)81656-6. DOI: https://doi.org/10.1016/S0092-8674(00)81656-6
  65. Pradhan S, Bacolla A, Wells RD, Roberts RJ. Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation. J Biol Chem. 1999;274(46):33002–10. doi: 10.1074/jbc.274.46.33002. DOI: https://doi.org/10.1074/jbc.274.46.33002
  66. Mortusewicz O, Schermelleh L, Walter J, et al. Recruitment of DNA methyltransferase I to DNA repair sites. Proc Natl Acad Sci USA. 2005;102(25):8905–9. doi: 10.1073/pnas.0501034102. DOI: https://doi.org/10.1073/pnas.0501034102
  67. Zebardast S, Sahmani M, Mohammadi S, et al. The Gene Expression Profile and DNA Methylation Pattern of CDH1 and DNMT1 Genes in Acute Promyelocytic Leukemia (APL). Rep Biochem Mol Biol. 2020;8(4):454–7.
  68. Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97(5):1172–9. doi: 10.1182/blood.v97.5.1172. DOI: https://doi.org/10.1182/blood.V97.5.1172
  69. Robaina MC, Mazzoccoli L, Arruda VO, et al. Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis. Exp Mol Pathol. 2015;98(2):200–7. doi: 10.1016/j.yexmp.2015.03.006. DOI: https://doi.org/10.1016/j.yexmp.2015.03.006
  70. Zhang TJ, Zhang LC, Xu ZJ, Zhou JD. Expression and prognosis analysis of DNMT family in acute myeloid leukemia. Aging (Albany NY). 2020;12(14):14677–90. doi: 10.18632/aging.103520. DOI: https://doi.org/10.18632/aging.103520
  71. Poole CJ, Zheng W, Lodh A, et al. DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt’s lymphoma. Oncotarget. 2017;8(44):76898–920. doi: 10.18632/oncotarget.20176. DOI: https://doi.org/10.18632/oncotarget.20176
  72. Amara K, Ziadi S, Hachana M, et al. DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. Cancer Sci. 2010;101(7):1722–30. doi: 10.1111/j.1349-7006.2010.01569.x. DOI: https://doi.org/10.1111/j.1349-7006.2010.01569.x
  73. Zhao H, Zhang LE, Guo S, et al. Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab. Oncol Lett. 2015;9(5):2307–12. doi: 10.3892/ol.2015.3038. DOI: https://doi.org/10.3892/ol.2015.3038
  74. Wang XX, Zhang H, Li Y. Preliminary study on the role of miR‑148a and DNMT1 in the pathogenesis of acute myeloid leukemia. Mol Med Rep. 2019;19(4):2943–52. doi: 10.3892/mmr.2019.9913. DOI: https://doi.org/10.3892/mmr.2019.9913
  75. Haque S, Vaiselbuh SR. Exosomal DNMT1 mRNA transcript is elevated in acute lymphoblastic leukemia which might reprograms leukemia progression. Cancer Genet. 2022;260–261:57–64. doi: 10.1016/j.cancergen.2021.07.004. DOI: https://doi.org/10.1016/j.cancergen.2021.07.004
  76. Li M, Qi L, Xu JB, et al. Methylation of the Promoter Region of the Tight Junction Protein-1 by DNMT1 Induces EMT-like Features in Multiple Myeloma. Mol Ther Oncolytics. 2020;19:197–207. doi: 10.1016/j.omto.2020.10.004. DOI: https://doi.org/10.1016/j.omto.2020.10.004
  77. Huang H, Jiang X, Li Z, et al. TET1 plays an essential oncogenic role in MLL–rearranged leukemia. Proc Natl Acad Sci USA. 2013;110(29):11994–9. doi: 10.1073/pnas.1310656110. DOI: https://doi.org/10.1073/pnas.1310656110
  78. Vitkevičienė A, Skliutė G, Žučenka A, et al. Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia. Cancers (Basel). 2022;14(11):2752. doi: 10.3390/cancers14112752. DOI: https://doi.org/10.3390/cancers14112752
  79. Huang Y, Wei J, Huang X, et al. Comprehensively analyze the expression and prognostic role for ten-eleven translocations (TETs) in acute myeloid leukemia. Transl Cancer Res. 2020;9(11):7259–83. doi: 10.21037/tcr-20-3149. DOI: https://doi.org/10.21037/tcr-20-3149
  80. Van Damme M, Crompot E, Meuleman N, et al. Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance. Clin Epigenetics. 2016;8:132. doi: 10.1186/s13148-016-0298-y. DOI: https://doi.org/10.1186/s13148-016-0298-y
  81. Zhang T, Zhao Y, Zhao Y, Zhou J. Expression and prognosis analysis of TET family in acute myeloid leukemia. Aging (Albany NY). 2020;12(6):5031–47. doi: 10.18632/aging.102928. DOI: https://doi.org/10.18632/aging.102928
  82. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol. 2005;22(2):367–77. doi: 10.1093/molbev/msi026. DOI: https://doi.org/10.1093/molbev/msi026
  83. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol. 2004;4(11):868–77. doi: 10.1038/nri1489. DOI: https://doi.org/10.1038/nri1489
  84. Ferreira PG, Jares P, Rico D, et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res. 2014;24(2):212–26. doi: 10.1101/gr.152132.112. DOI: https://doi.org/10.1101/gr.152132.112
  85. Cifola I, Lionetti M, Pinatel E, et al. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget. 2015;6(19):17543–58. doi: 10.18632/oncotarget.4028. DOI: https://doi.org/10.18632/oncotarget.4028
  86. Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood. 2018;131(24):2670–81. doi: 10.1182/blood-2017-11-817601. DOI: https://doi.org/10.1182/blood-2017-11-817601
  87. Bhutani N, Brady JJ, Damian M, et al. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature. 2010;463(7284):1042–7. doi: 10.1038/nature08752. DOI: https://doi.org/10.1038/nature08752
  88. Conticello SG. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 2008;9(6):229. doi: 10.1186/gb-2008-9-6-229. DOI: https://doi.org/10.1186/gb-2008-9-6-229
  89. Rogozin IB, Basu MK, Jordan IK, et al. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle. 2005;4(9):1281–5. doi: 10.4161/cc.4.9.1994. DOI: https://doi.org/10.4161/cc.4.9.1994
  90. Muto T, Muramatsu M, Taniwaki M, et al. Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene. Genomics. 2000;68(1):85–8. doi: 10.1006/geno.2000.6268. DOI: https://doi.org/10.1006/geno.2000.6268
  91. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature. 2012;489(7414):101–8. doi: 10.1038/nature11233. DOI: https://doi.org/10.1038/nature11233
  92. Schmitt AM, Chang HY. Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 2016;29(4):452–63. doi: 10.1016/j.ccell.2016.03.010. DOI: https://doi.org/10.1016/j.ccell.2016.03.010
  93. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66. doi: 10.1038/nrc1997. DOI: https://doi.org/10.1038/nrc1997
  94. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97. doi: 10.1016/s0092-8674(04)00045-5. DOI: https://doi.org/10.1016/S0092-8674(04)00045-5
  95. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66(15):7390–4. doi: 10.1158/0008-5472.CAN-06-0800. DOI: https://doi.org/10.1158/0008-5472.CAN-06-0800
  96. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92. doi: 10.1016/j.cell.2007.01.029. DOI: https://doi.org/10.1016/j.cell.2007.01.029
  97. Aran D, Sabato S, Hellman A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol. 2013;14(3):R21. doi: 10.1186/gb-2013-14-3-r21. DOI: https://doi.org/10.1186/gb-2013-14-3-r21
  98. Bird A, Taggart M, Frommer M, et al. A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell. 1985;40(1):91–9. doi: 10.1016/0092-8674(85)90312-5. DOI: https://doi.org/10.1016/0092-8674(85)90312-5
  99. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol. 1987;196(2):261–82. doi: 10.1016/0022-2836(87)90689-9. DOI: https://doi.org/10.1016/0022-2836(87)90689-9
  100. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA. 2002;99(6):3740–5. doi: 10.1073/pnas.052410099. DOI: https://doi.org/10.1073/pnas.052410099
  101. Maunakea AK, Nagarajan RP, Bilenky M, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010;466(7303):253–7. doi: 10.1038/nature09165. DOI: https://doi.org/10.1038/nature09165
  102. Stadler MB, Murr R, Burger L, et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature. 2011;480(7378):490–5. doi: 10.1038/nature10716. DOI: https://doi.org/10.1038/nature10716
  103. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011;25(10):1010–22. doi: 10.1101/gad.2037511. DOI: https://doi.org/10.1101/gad.2037511
  104. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA. 2006;103(5):1412–7. doi: 10.1073/pnas.0510310103. DOI: https://doi.org/10.1073/pnas.0510310103
  105. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 1993;366(6453):362–5. doi: 10.1038/366362a0. DOI: https://doi.org/10.1038/366362a0
  106. Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37(11):1012–27. doi: 10.1016/j.tig.2021.05.002. DOI: https://doi.org/10.1016/j.tig.2021.05.002
  107. Laird PW, Jaenisch R. DNA methylation and cancer. Hum Mol Genet. 1994;3(Spec No):1487–95. doi: 10.1093/hmg/3.suppl_1.1487. DOI: https://doi.org/10.1093/hmg/3.suppl_1.1487
  108. Niederwieser C, Kohlschmidt J, Volinia S, et al. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2015;29(3):567–75. doi: 10.1038/leu.2014.267. DOI: https://doi.org/10.1038/leu.2014.267
  109. Kalinkova L, Sevcikova A, Stevurkova V, et al. Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool. Int J Mol Sci. 2022;24(1):633. doi: 10.3390/ijms24010633. DOI: https://doi.org/10.3390/ijms24010633
  110. Hetzel S, Mattei AL, Kretzmer H, et al. Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nat Cancer. 2022;3(6):768–82. doi: 10.1038/s43018-022-00370-5. DOI: https://doi.org/10.1038/s43018-022-00370-5
  111. Bensberg M, Rundquist O, Selimović A, et al. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2021;118(34):e2110758118. doi: 10.1073/pnas.2110758118. DOI: https://doi.org/10.1073/pnas.2110758118
  112. Letafati A, Mehdigholian Chaijani R, Edalat F, et al. Advances in epigenetic treatment of adult T-cell leukemia/lymphoma: a comprehensive review. Clin Epigenetics. 2025;17(1):39. doi: 10.1186/s13148-025-01841-z. DOI: https://doi.org/10.1186/s13148-025-01841-z
  113. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28(4):605–13. doi: 10.1200/JCO.2009.23.4781. DOI: https://doi.org/10.1200/JCO.2009.23.4781
  114. Noguera-Castells A, Campillo-Marcos I, Davalos V, et al. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study. Br J Haematol. 2024;204(5):1838–43. doi: 10.1111/bjh.19392. DOI: https://doi.org/10.1111/bjh.19392
  115. Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol. 2006;76(1):23–32. doi: 10.1111/j.1600-0609.2005.00559.x. DOI: https://doi.org/10.1111/j.1600-0609.2005.00559.x
  116. Yamazaki J, Taby R, Vasanthakumar A, et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 2012;7(2):201–7. doi: 10.4161/epi.7.2.19015. DOI: https://doi.org/10.4161/epi.7.2.19015
  117. Muylaert C, Van Hemelrijck LA, Maes A, et al. Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity? Front Oncol. 2022;12:979569. doi: 10.3389/fonc.2022.979569. DOI: https://doi.org/10.3389/fonc.2022.979569
  118. Duran-Ferrer M, Martín-Subero JI. Epigenomic Characterization of Lymphoid Neoplasms. Annu Rev Pathol. 2024;19:371–96. doi: 10.1146/annurev-pathmechdis-051122-100856. DOI: https://doi.org/10.1146/annurev-pathmechdis-051122-100856
  119. Salhia B, Baker A, Ahmann G, et al. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res. 2010;70(17):6934–44. doi: 10.1158/0008-5472.CAN-10-0282. DOI: https://doi.org/10.1158/0008-5472.CAN-10-0282
  120. Heuck CJ, Mehta J, Bhagat T, et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol. 2013;190(6):2966–75. doi: 10.4049/jimmunol.1202493. DOI: https://doi.org/10.4049/jimmunol.1202493
  121. Tuncel FC, Serin I, Pehlivan S, et al. Epigenetic and genetic investigation of SOCS-1 gene in patients with multiple myeloma. Blood Res. 2022;57(4):250–5. doi: 10.5045/br.2022.2022097. DOI: https://doi.org/10.5045/br.2022.2022097
  122. Zhang X, Wang H, Zhang Y, Wang X. Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment. Clin Exp Med. 2024;24(1):54. doi: 10.1007/s10238-023-01268-x. DOI: https://doi.org/10.1007/s10238-023-01268-x
  123. Maiques-Diaz A, Martin-Subero JI. Biological, prognostic, and therapeutic impact of the epigenome in CLL. Semin Hematol. 2024;61(3):172–80. doi: 10.1053/j.seminhematol.2023.11.005. DOI: https://doi.org/10.1053/j.seminhematol.2023.11.005
  124. Siref A, McCormack C, Huang Q, et al. Diminished expression of 5hmc in Reed-Sternberg cells in classical Hodgkin lymphoma is a common epigenetic marker. Leuk Res. 2020;96:106408. doi: 10.1016/j.leukres.2020.106408. DOI: https://doi.org/10.1016/j.leukres.2020.106408
  125. Clozel T, Yang S, Elstrom RL, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 2013;3(9):1002–19. doi: 10.1158/2159-8290.CD-13-0117. DOI: https://doi.org/10.1158/2159-8290.CD-13-0117
  126. Kretzmer H, Bernhart SH, Wang W, et al. DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. Nat Genet. 2015;47(11):1316–25. doi: 10.1038/ng.3413. DOI: https://doi.org/10.1038/ng.3413
  127. Kurdyukov S, Bullock M. DNA Methylation Analysis: Choosing the Right Method. Biology (Basel). 2016;5(1):3. doi: 10.3390/biology5010003. DOI: https://doi.org/10.3390/biology5010003
  128. Bernstein BE, Stamatoyannopoulos JA, Costello JF, et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol. 2010;28(10):1045–8. doi: 10.1038/nbt1010-1045. DOI: https://doi.org/10.1038/nbt1010-1045
  129. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA. 1992;89(5):1827–31. doi: 10.1073/pnas.89.5.1827. DOI: https://doi.org/10.1073/pnas.89.5.1827
  130. Herman JG, Graff JR, Myöhänen S, et al. Methylation–specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821–6. doi: 10.1073/pnas.93.18.9821. DOI: https://doi.org/10.1073/pnas.93.18.9821
  131. Rauluseviciute I, Drabløs F, Rye MB. DNA methylation data by sequencing: experimental approaches and recommendations for tools and pipelines for data analysis. Clin Epigenetics. 2019;11(1):193. doi: 10.1186/s13148-019-0795-x. DOI: https://doi.org/10.1186/s13148-019-0795-x
  132. Meissner A, Gnirke A, Bell GW, et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 2005;33(18):5868–77. doi: 10.1093/nar/gki901. DOI: https://doi.org/10.1093/nar/gki901
  133. Gupta R, Nagarajan A, Wajapeyee N. Advances in genome-wide DNA methylation analysis. Biotechniques. 2010;49(4):iii–xi. doi: 10.2144/000113493. DOI: https://doi.org/10.2144/000113493
  134. Скрябин Н.А., Кашеварова А.А., Денисов Е.В., Лебедев И.Н. Методы исследования метилирования ДНК: возможности и перспективы использования в онкологи. Сибирский онкологический журнал. 2013;1(6):64–9. [Skryabin N.A., Kashevarova A.A., Denisov E.V., Lebedev I.N. Methods of DNA methylation analysis: possibilities and limitations of their application in oncology. Siberian journal of oncology. 2013;1(6):64–9. (In Russ)]
  135. Bonora G, Rubbi L, Morselli M, et al. DNA methylation estimation using methylation-sensitive restriction enzyme bisulfite sequencing (MREBS). PLoS One. 2019;14(4):e0214368. doi: 10.1371/journal.pone.0214368. DOI: https://doi.org/10.1371/journal.pone.0214368
  136. Issa JJ, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16(9):1099–110. doi: 10.1016/S1470-2045(15)00038-8. DOI: https://doi.org/10.1016/S1470-2045(15)00038-8
  137. Dhillon S. Decitabine/Cedazuridine: First Approval. Drugs. 2020;80(13):1373–8. doi: 10.1007/s40265-020-01389-7. DOI: https://doi.org/10.1007/s40265-020-01389-7
  138. Klisovic RB, Stock W, Cataland S, et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008;14(8):2444–9. doi: 10.1158/1078-0432.CCR-07-1320. DOI: https://doi.org/10.1158/1078-0432.CCR-07-1320

Keywords:

epigenetics, DNA methylation, bisulfite conversion, hematologic malignancies

License

Copyright (c) 2026 Clinical Oncohematology. Basic Research and Clinical Practice

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.
2026-1

Downloads

Published

01.01.2026

Issue

Vol. 19 No. 1 (2026)
ORIGINAL ARTICLES

How to Cite

Mikhaleva M.A., Zherniakova A.A., Krysiuk O.B., Sidorkevich S.V. Gene Methylation Profile in Hematologic Malignancies. Clinical Oncohematology. Basic Research and Clinical Practice. 2026;19(1):27–38. doi:10.21320/2500-2139-2026-19-1-27-38.

Most read articles by the same author(s)